Physician profile
Danielle Arcaro
NPI 1962495457
$6,711.78
in general payments reported to CMS, 2019-2025
28 companies · $1,961 in 2025
The $1,961 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $288 · 2021: $740 · 2022: $620 · 2023: $662 · 2024: $1,755 · 2025: $1,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,378.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $826.06 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $702.61 | 2024-2025 | Xdemvy |
| Amgen INC. | $665.14 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $429.09 | 2022-2025 | Clareon, Constellation, Eysuvis |
| Mallinckrodt Hospital Products INC. | $355.68 | 2023-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $323.63 | 2019-2025 | Eylea, Eylea Hd |
| Abbvie INC. | $312.51 | 2022-2024 | Ozurdex |
| New World Medical,INC. | $297.71 | 2020-2021 | |
| Allergan, INC. | $274.06 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $272.44 | 2019-2025 | Cequa |
| Eyevance Pharmaceuticals LLC | $238.41 | 2021 | |
| Harrow Eye, LLC | $238.29 | 2024-2025 | Vevye |
| Genentech USA, INC. | $191.28 | 2023-2025 | Vabysmo |
| Dompe US, INC. | $183.49 | 2021-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $175.31 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $164.92 | 2021-2022 | |
| Horizon Therapeutics Plc | $161.80 | 2020-2023 | Tepezza |
| Sight Sciences, INC. | $145.22 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $132.42 | 2019-2023 | |
| Astellas Pharma US INC | $121.00 | 2024-2025 | Izervay |
| Ivantis, INC | $116.62 | 2019 | |
| Oyster Point Pharma, INC. | $109.31 | 2022-2024 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $99.66 | 2024 | Idose |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $72.00 | 2021 | |
| Thea Pharma INC. | $42.02 | 2022-2023 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $25.66 | 2024 | Catalys System |
| Akorn Operating Company LLC | $19.67 | 2021 | |
| Shire North American Group INC | $15.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Arcaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.